Afrezza Inhalant Product
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Treated With Insulin
Conditions
Type 2 Diabetes Treated With Insulin
Trial Timeline
Feb 27, 2019 → Mar 15, 2020
NCT ID
NCT04125082About Afrezza Inhalant Product
Afrezza Inhalant Product is a approved stage product being developed by Dexcom for Type 2 Diabetes Treated With Insulin. The current trial status is unknown. This product is registered under clinical trial identifier NCT04125082. Target conditions include Type 2 Diabetes Treated With Insulin.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Treated With Insulin were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04125082 | Approved | UNKNOWN |
Competing Products
20 competing products in Type 2 Diabetes Treated With Insulin